Latest Production Development News

Advanced Braking Technology (ASX: ABV) posted a record $6.2 million in product sales for Q4 FY26, lifting full-year revenue 22.7% to $23.5 million. The company’s autonomous BRAKEiQ system advanced key milestones as international engagement expanded.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

De.mem Limited posted its second highest quarterly cash receipts of approximately $9.6 million for June 2026, marking 29 consecutive quarters of growth and positive operating cash flow of $424k. The company’s strong half-year performance is underpinned by recurring revenues, a robust Western Australian business, and record results from its German subsidiary.

Appen's Q2 FY26 results highlight a robust 26% revenue increase, driven by a 75% jump in its China segment and improving global operations. The company reiterates its full-year guidance amid ongoing AI market growth and operational efficiencies.

Stakk Ltd (ASX: SKK) has reported unaudited FY2026 revenue of A$14.68 million, beating prior guidance and delivering a 1,298% surge in customer cash receipts. The company also posted positive operating cash flow for the June quarter and anticipates further growth through its pending ParaScript acquisition.

Green360 Technologies has sealed its first binding supply contract with Holcim and ramped up MKX production, positioning itself as Australia’s leading supplier of low-carbon cement alternatives amid tightening SCM markets.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

Artrya is advancing its commercial footprint in the US with two health systems now generating revenue and FDA clearance for its Salix Coronary Flow module expected in H2 2026.

xReality Group delivered a robust Q4 FY26, with cash receipts up 46% to $6.9 million and net operating cash flow rising 64% to $2.2 million. The company completed a $5.6 million US Department of Defense project on time and secured its first European contract with the Swedish Armed Forces.

Saluda Medical capped FY26 with a 28% revenue surge, beating guidance at US$90.2 million, while FDA approval for its CAP24 paddle lead opens a new US surgical market segment.

Australian Silica Quartz Group (ASQ) reports promising kaolin beneficiation results from its White Swan Project, with dry processing boosting kaolinite content to 83% and early ceramic tests confirming product quality. Chinese market feedback signals robust demand amid dwindling domestic supplies.